100 related articles for article (PubMed ID: 8995517)
21. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Orr RM; O'Neill CF; Nicolson MC; Barnard CF; Murrer BA; Giandomenico CM; Vollano JF; Harrap KR
Br J Cancer; 1994 Sep; 70(3):415-20. PubMed ID: 8080724
[TBL] [Abstract][Full Text] [Related]
22. A new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV) complex: trans-(n-valerato)chloro(1R,2R-cyclohexanediamine) (oxalato)platinum(IV).
Kizu R; Nakanishi T; Hayakawa K; Matsuzawa A; Eriguchi M; Takeda Y; Akiyama N; Tashiro T; Kidani Y
Cancer Chemother Pharmacol; 1999; 43(2):97-105. PubMed ID: 9923814
[TBL] [Abstract][Full Text] [Related]
23. Antitumor-activity of orally-administered ammine amine platinum (iv) dicarboxylate complexes against a panel of human ovarian-carcinoma xenografts.
Kelland L; Jones M; Gwynne J; Valenti M; Murrer B; Barnard C; Vollano J; Giandomenico C; Abrams M; Harrap K
Int J Oncol; 1993 Jun; 2(6):1043-8. PubMed ID: 21573668
[TBL] [Abstract][Full Text] [Related]
24. The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study.
Ormerod MG; Orr RM; O'Neill CF; Chwalinski T; Titley JC; Kelland LR; Harrap KR
Br J Cancer; 1996 Dec; 74(12):1935-43. PubMed ID: 8980393
[TBL] [Abstract][Full Text] [Related]
25. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration.
McKeage MJ; Mistry P; Ward J; Boxall FE; Loh S; O'Neill C; Ellis P; Kelland LR; Morgan SE; Murrer B
Cancer Chemother Pharmacol; 1995; 36(6):451-8. PubMed ID: 7554035
[TBL] [Abstract][Full Text] [Related]
26. Comparative distribution and excretion of carboplatin and cisplatin in mice.
Siddik ZH; Jones M; Boxall FE; Harrap KR
Cancer Chemother Pharmacol; 1988; 21(1):19-24. PubMed ID: 3277732
[TBL] [Abstract][Full Text] [Related]
27. Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent.
Ando Y; Shimizu T; Nakamura K; Mushiroda T; Nakagawa T; Kodama T; Kamataki T
Br J Cancer; 1998 Nov; 78(9):1170-4. PubMed ID: 9820175
[TBL] [Abstract][Full Text] [Related]
28. Liver organotropism and biotransformation of a novel platinum-ursodeoxycholate derivative, Bamet-UD2, with enhanced antitumour activity.
Larena MG; Martinez-Diez MC; Monte MJ; Dominguez MF; Pascual MJ; Marin JJ
J Drug Target; 2001 Jun; 9(3):185-200. PubMed ID: 11697204
[TBL] [Abstract][Full Text] [Related]
29. Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.
Theiner S; Varbanov HP; Galanski MS; Egger AE; Berger W; Heffeter P; Keppler BK
J Biol Inorg Chem; 2015 Jan; 20(1):89-99. PubMed ID: 25413442
[TBL] [Abstract][Full Text] [Related]
30. Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents.
McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
Br J Cancer; 1993 May; 67(5):996-1000. PubMed ID: 8494733
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and oral antitumor activity of tetrakis(carboxylato)platinum(IV) complexes.
Lee YA; Lee SS; Kim KM; Lee CO; Sohn YS
J Med Chem; 2000 Apr; 43(7):1409-12. PubMed ID: 10753477
[TBL] [Abstract][Full Text] [Related]
32. In vitro binding of an orally active platinum antitumor drug, JM216 to metallothionein.
Xing B; Zhu H; Shi Y; Tang W
Biometals; 2001 Mar; 14(1):51-7. PubMed ID: 11368275
[TBL] [Abstract][Full Text] [Related]
33. Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates.
Poon GK; Mistry P; Raynaud FI; Harrap KR; Murrer BA; Barnard CF
J Pharm Biomed Anal; 1995 Nov; 13(12):1493-8. PubMed ID: 8788134
[TBL] [Abstract][Full Text] [Related]
34. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients.
Fokkema E; de Vries EG; Meijer S; Groen HJ
Cancer Chemother Pharmacol; 2000; 45(1):89-92. PubMed ID: 10647508
[TBL] [Abstract][Full Text] [Related]
35. Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy.
Amorino GP; Mohr PJ; Hercules SK; Pyo H; Choy H
Cancer Chemother Pharmacol; 2000; 46(5):423-6. PubMed ID: 11127948
[TBL] [Abstract][Full Text] [Related]
36. Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.
Thompson DC; Vaisman A; Sakata MK; Wyrick SD; Holbrook DJ; Chaney SG
Cancer Chemother Pharmacol; 1995; 36(5):439-47. PubMed ID: 7634386
[TBL] [Abstract][Full Text] [Related]
37. A new platinum-complex showing easy preparation, promising anti-tumor activity, and better efficacy and distribution properties than oxaliplatin.
Wang Y; Kang G; Zhao M; Wu J; Zhang X; Yang Y; Liu J; Peng S
Mol Biosyst; 2011 Dec; 7(12):3245-52. PubMed ID: 22008999
[TBL] [Abstract][Full Text] [Related]
38. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological activity of novel platinum(II) complexes of glutamate tethered to hydrophilic hematoporphyrin derivatives.
Kim YS; Song R; Lee CO; Sohn YS
Bioorg Med Chem Lett; 2004 Jun; 14(11):2889-92. PubMed ID: 15125953
[TBL] [Abstract][Full Text] [Related]
40. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition.
Amorino GP; Freeman ML; Carbone DP; Lebwohl DE; Choy H
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):399-405. PubMed ID: 10760436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
